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Abstract The protease inhibitor neuroserpin regulates the
development of the nervous system and its plasticity in the adult.
Neuroserpins carrying the Ser53Pro or Ser56Arg mutation form
polymers in neuronal cells. We describe here the structure of
wild-type neuroserpin in a cleaved form. The structure provides a
basis to understand the role of the mutations in the polymeriza-
tion process. We propose that these mutations could delay the
insertion of the reactive center loop into the central L-sheet A, an
essential step in the inhibition and possibly in the polymerization
of neuroserpin. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Neuroserpin is a serine protease inhibitor belonging to the
serpin family [1,2]. It is expressed in neurons of the central
and peripheral nervous system in the adult and during devel-
opment [3]. Complex formation and inhibition assays have
demonstrated that it is a potent inhibitor of tissue-type plas-
minogen activator (tPA), urokinase plasminogen activator
and plasmin. In contrast, no inhibition of thrombin activity
was observed [4,5]. Studies of the interactions between neuro-
serpin and its target proteases indicate that it acts, like other
serpins, as a suicide inhibitor by forming an extremely stable
acyl complex with its target proteases. Inhibition involves
cleavage of the reactive center loop (RCL) between residues
P1 and P1P [6], and insertion of its N-terminal portion into L-
sheet A. We have determined the structure of neuroserpin in
its cleaved form. Our crystallographic results indicate that
residues P1 and P1P are separated by 70 Aî (Fig. 1), as it
was observed in the structure of human K1-proteinase inhib-
itor [7]. RCL insertion into L-sheet A critically depends on a
sliding mechanism: L-strand s3A, belonging to L-sheet A,
slides over the so-called shutter region [8], that is the end of
L-strand s6B and the beginning of K-helix hB (blue in Fig. 1,
see also legend). Mutations in the shutter region a¡ect RCL
insertion and impair the inhibition mechanism (for a review,
see [9]). In some cases, such mutations lead to the formation
of serpin polymers [9]. Recently, two point mutants of neuro-
serpin (Ser53Pro and Ser56Arg, nomenclature de¢ned by Loe-
bermann et al. [7]) were discovered in two families su¡ering
from presenile dementia. In both families, the a¡ected indi-
viduals underwent progressive neuronal degeneration due to
the formation of inclusion bodies composed of polymerized
uncleaved mutant neuroserpin in the cerebral cortex [10]. Both
point mutants belong to the shutter region.
Based on our crystal structure, we discuss the possible e¡ect
of the two mutants associated with pathogenic polymeriza-
tion. We propose that the two mutations could a¡ect the
rate of loop insertion.
2. Materials and methods
2.1. Expression and puri¢cation of mouse neuroserpin (mNS)
The construct used for expressing homogenous neuroserpin in
Escherichia coli was designed with a deletion of the last 13 amino
acids at the C-terminus. Using the mNS cDNA encoding amino acids
17^410 cloned in the pAK400 vector [11] via the NdeI and HindIII
sites without the pelB leader as a template [3], a polymerase chain
reaction (PCR) was performed with Pfu polymerase (Stratagene) ac-
cording to the manufacturer’s protocol. The ampli¢cation was per-
formed with the primer pair 5P-agcatatgacaggggcaacgttcccagatg-3P
(NdeI site is underlined) and 5P-tcaagcTTATTAatggtgatggtgatgat-
gagggttcatgactcgtcccatg-3P (HindIII site is underlined, His-tag se-
quence is indicated in italics, two ochre-stop codons are capitalized).
The resulting PCR product was veri¢ed by sequencing of both
strands, digested with NdeI and HindIII and ligated into the
pAK400 vector. Expression and puri¢cation were performed as de-
scribed by Krueger et al. [3]. A hydrophobic interaction chromatog-
raphy was included. After adding ammonium sulfate to obtain a ¢nal
concentration of 1.5 M, the protein solution was loaded onto a HP
phenyl Sepharose XK16 (Pharmaciaz) column. The protein was
eluted using a gradient from 900 mM to 0 mM ammonium sulfate
in PS bu¡er (200 mM Tris^HCl pH 8.0, 50 mM NaCl) over 10 col-
umn volumes. Fractions containing the pure, uncleaved protein were
pooled and dialyzed against a storage bu¡er (10 mM Tris^HCl pH
8.0, 50 mM NaCl).
2.2. Complex formation assay and amidolytic assay
Complex formation assays and amidolytic assays were performed as
described by Krueger et al. [3] with recombinant human tPA (Gen-
entech, South San Francisco, CA, USA) and human thrombin (Sig-
ma, St. Louis, MO, USA).
2.3. Crystallization, data collection and processing
Prior to crystallization, mNS was cleaved with 1:3 of trypsin from
bovine pancreas (Fluka, 93608) overnight at 4‡C in 50 mM Tris^HCl
pH 8.4, 200 mM NaCl, 0.3 mM CaCl2. The protein was then puri¢ed
with a MonoQ HR10/10 column (Pharmaciaz) using a bu¡er contain-
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ing 20 mM Tris^HCl pH 8.0, 0.1 mM phenylmethylsulfonyl £uoride
and a gradient from 200 mM to 400 mM NaCl on 40 column vol-
umes. Fractions containing the pure cleaved protein were pooled,
concentrated to 25 mg/ml using a Centricon YM-10 (Amicon, Milli-
pore) and bu¡er was exchanged with the storage bu¡er. A single
crystal was used for data collection. It was grown over 1 week at
20‡C from a sitting drop of 1:1 mixture of the protein sample and
a reservoir solution containing 25% PEG8000, 0.2 M H2PO4(NH4),
0.1 M Tris^HCl pH 6.1. The crystal exhibited initial di¡raction to
2.7 Aî resolution. The space group was found to be P21 (a = 64.3 Aî ,
b = 108.7 Aî , c = 46.0 Aî , L= 101.3‡). A dataset was collected at 100 K
with a 300 mm Mar Research Image plate using CuKK radiation
(Nonius generator FR571 operating at 45 kV, 95 mA), focused by a
double mirror system from Prophysics (XRM-216). The data (see
Table 1) were processed with Denzo and scaled with Scalepack [12].
2.4. Structure determination and re¢nement
The structure was solved by molecular replacement using the pro-
gram AmoRe [13] and a polyserine consensus model, based on
10 cleaved serpin structures [7,14^18], generated using Modeller [19].
Using the data from 10 Aî to 4 Aî , AmoRe indicated the presence of
two molecules in the asymmetric unit related by a non-crystallo-
graphic symmetry (NCS) axis. Both translation solutions had an
R-value of 47.1% and a correlation coe⁄cient of 38.1%. The solvent
content was determined to be 30% [20]. Density modi¢cation (solvent
£attening, histogram matching and 2-fold averaging) with DM [21]
yielded phases of su⁄cient quality to build a model of neuroserpin
containing most side chains. The program O was used for this pur-
pose [22]. After rigid-body re¢nement with CNS [23], torsion angle
simulated annealing was performed with 2-fold NCS constraints
(CNS). A bulk solvent correction (17^3.06 Aî ) was applied as well
as an anisotropy correction (8^3.06 Aî ). Additional cycles of rebuilding
and re¢nement, followed by an individual B-factor re¢nement, yielded
a crystallographic R-value of 23.2% and an Rfree of 30.8%. The atomic
coordinates have been deposited with the Brookhaven Protein Data
Bank (PDB; code 1JJO).
3. Results and discussion
3.1. Crystallization and activity tests of recombinant
neuroserpin
Sequence alignment with other previously crystallized ser-
pins reveals that mNS possesses 13 additional residues at the
C-terminus. We cloned neuroserpin in a bacterial expression
system without those 13 residues to avoid a possible tail that
could create structural heterogeneities, hampering crystalliza-
tion. The C-terminally truncated form (mNSd13C) was tested
in vitro for activity and was found to be as active as wild-type
mNS prepared as described by Krueger et al. [3] (Fig. 2A).
The ability of mNSd13C and mNS to inhibit the amidolytic
activity of tPA and thrombin on a chromogenic substrate
(D-isoleucyl-L-propyl-L-arginine-p-nitroaniline-dihydrochloride,
Chromogenix, Mo«lndal, Sweden) was also compared (Fig.
2B). The inhibition level of mNSd13C was the same as pre-
viously observed by Krueger et al. for mNS [3].
Various attempts to crystallize uncleaved mNSd13C were
not successful, possibly the £exibility of the RCL prevents
the regular arrangement of the molecule into a crystal lattice.
We therefore tried to crystallize a cleaved form of mNSd13C.
Trypsin digestion was used to produce a cleaved species that
crystallized.
3.2. Structure description
The structure of the cleaved form of mNSd13C reveals a
cleaved RCL and a deletion of a segment comprising residues
69^106 (K-helices hC, hD and connecting loop). The topology
of neuroserpin (Fig. 1) is identical to that of other cleaved
serpin structures [7,14^18,24]. Although marked sequence dif-
ferences exist between di¡erent serpins, structural di¡erences
Fig. 1. Ribbon diagram of mNSd13C. Secondary structure elements
are labeled according to Loebermann et al. [7]. The ‘shutter region’
is colored in blue [8]. The RCL (in red) is inserted after cleavage
into the L-sheet A (in green) to form the L-strand s4A. The RCL
also forms the L-strand s1C of the L-sheet C (in purple). A 2Fo3Fc
electron density map (1c contour) shows the presence of the
L-strand s4A.
Table 1
Crystallographic data
Cell parameters (space group P21)
a (Aî ) 64.3
b (Aî ) 108.7
c (Aî ) 46.0
K (‡) 90.0
L (‡) 101.3
Q (‡) 90.0
No. molecules per asymmetric unit 2
Data collection
Resolution limits (Aî ) 17.00^3.06
No. unique re£ections 9419 (7975)a
Redundancy 2.57
Completeness (%) 79.7 (74.6)b
Average I/c 5.8 (2.0)b
Rsym(I)c (%) 15.5 (42.2)b
Re¢nement
Rdfactor (%) 23.2
Refree (%) 30.8
Rmsd bonds (Aî ) 0.008
Rmsd angles (‡) 1.42
as 2c.
bStatistics for the highest resolution shell (3.14^3.06 Aî ).
cRsym(I) =ghklgjMIj;hkl3GIhklfM/ghklgj;hkl , where GIhklf is the average of
the intensity Ij;hkl over j = 1, T, N observations of symmetry equiva-
lent re£ections hkl.
dRfactor =gMMFoM3MFcMM/gMFoM, where MFoM and MFcM are observed
and scaled calculated structure factor amplitudes respectively. The
Rfactor is calculated on 8914 re£ections (75.5%).
e4.3% of the data (505 re£ections).
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are only seen in loop regions, resulting mainly from the var-
iable loop lengths. Compared to the ¢rst cleaved K1-antipro-
teinase structure [7], mNSd13C contains the following addi-
tional residues: 179A to 179B, 235A to 235F, 246A, 258A.
A complete insertion of the RCL into L-sheet A to form
L-strand s4A is observed. As expected for a functional inhib-
itor, mNSd13C cleaved by trypsin shows the expected relaxed
serpin form and not the stressed form of plakalbumin [25]
where the RCL is cleaved but not inserted. The loop compris-
ing residues 311^327 (before L-strand s5A) is not visible in the
structure, but its presence was proven by matrix-assisted laser
desorption ionization mass spectrometry performed on pro-
tein from dissolved crystals. Similarly, a part of the corre-
sponding loop in the crystal structure of antithrombin (PDB
code 1AHT, residues B356^B361) [26] was also missing, indi-
cating £exibility in this region. Likewise, no electron density
was found for residues P1 and P1P to P4P.
3.3. Model building and role of residues Ser53 and Ser56
during the insertion of the RCL
Using the crystal structures of mNSd13C (present work),
K1-antitrypsin [27], plasminogen activator inhibitor 2 [28] and
preinserted antithrombin as templates [26], models of the na-
tive and preinserted forms of neuroserpin were created. Ser53-
Pro and Ser56Arg models were also created. The hydrogen
Fig. 3. Ser53 and Ser56 and the insertion of RCL: a model. A: The
‘shutter region’ in the native form (in dark blue, template K1-anti-
trypsin [27]). A ring of hydrogen bonds links the side chain of
Ser56, His334 and Asn186. B: After preinsertion of the RCL (in
green), His334 must rotate and interact with the backbone CNO of
Asn186. During the preinsertion of the RCL, Val188 slides between
Ser53 and Ser56 (Fig. 4A), so Ser56 must also rotate. Consequently,
Asn186 has to rotate to maintain its interaction with Ser56 (anti-
thrombin structure used as a template [26]). C: Asn186 continues to
slide between residues 56 and 60 (Fig. 4A). Its side chain rotates to
a similar position as seen in the native form. Ser351 takes the place
of Asn186 and the L-strand s3A translocates from its preinserted
position to its relaxed position (in orange; structure of neuroserpin).
The loss of the hydrogen bond between Asn186 and His334 is com-
pensated for by the formation of a hydrogen bond with the OH
side chain of Ser351. Prepared with Setor [31].
Fig. 2. Activity tests. A: Analysis of the complex formation of
mNS and of C-terminally truncated neuroserpin (mNSd13C) with
tPA and thrombin. Since neuroserpin forms sodium dodecyl sulfate-
stable complexes with tPA but not with thrombin [4,5], 5 WM mNS
or mNSd13C was incubated with 5 WM of tPA or thrombin. Neuro-
serpin or neuroserpin-containing complexes were detected by West-
ern blot. For both mNS and mNSd13C, two complexes with tPA
were found with an apparent molecular weight (MW) that corre-
sponds to the sum of the MW of the neuroserpin and of a single-
chain tPA or a double-chain tPA. In contrast, no thrombin-contain-
ing complex was observed. The possible cross-reactivity of the anti-
serum with tPA was ¢rst checked and found to be negative (data
not shown). B: mNS and mNSd13C similarly inhibit the amidolytic
activity of tPA but fail to inhibit thrombin. tPA or thrombin (8 nM)
were preincubated with various concentrations of both neuroserpins.
The protease substrate D-isoleucyl-L-prolyl-L-arginine-p-nitroaniline
was added and p-nitroaniline release was measured.
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bonding pattern of the shutter region was analyzed in the
models of native and preinserted neuroserpin, and in the crys-
tal structure (cleaved form) (Fig. 3A^C). This analysis sug-
gests that Ser53 should maintain its structurally important
interactions in all three forms without any rotation of its
side chain during the transition from the native to the fully
inserted form. In contrast, Ser56 (Fig. 3A^C) has to rotate
during this transition [28]. On the other hand, Val188 has to
slide between Ser53 and Ser56 (Fig. 4A). Mutations of Ser53
or Ser56 could a¡ect the sliding of Val188 and then impair the
full insertion of the RCL. Analysis of Ser53Pro and Ser56Arg
models suggests that these two point mutations could lead to
a decrease in the rate of conversion of the preinserted form to
the relaxed (latent or cleaved) form (Fig. 4B,C). A preinserted
form of neuroserpin would therefore be accumulated in the
mutants and could be the reason for their tendency to poly-
merize. We hypothesize that polymerization could occur by
insertion of the RCL of one preinserted molecule into the
bottom part of the central L-sheet A of a second molecule.
This mechanism is in accordance with previous proposals of
polymer models [27,29,30]. In order to prove experimentally
the role of mutations Ser53Pro and Ser56Arg we will prepare
the mutant molecules and analyze the e¡ect of the mutations
on the aggregation behavior. This experiment will be carried
out on both cleaved and native mNS.
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